MYC and neoplasm: Stage-specific miRNAs play a crucial role in CRC treatment; miR-196 regulates tumor development, progression, and response to therapy, while miR-27b-3p is involved in oxaliplatin resistance and modulates chemotherapy sensitivity through the c-Myc/miR-27b-3p/ATG10 axis.